The Cancer Immunology (CI) Research Program evolved from the former Immunology and Immunotherapy research program. The previous immunology and Immunotherapy program was centered around basic immunology wherein only some investigators had cancer immunology as their primary interest In contrast, the present CI program has cancer-directed immunology research as its nucleus, supported by the research and fertile environment provided by the more basic immunology community at Yale. Several programmatic developments enabled this evolution;First, new recruitments have bolstered cancer immunology research. Secondly, existing CI members have expanded their research efforts in cancer-specific studies. Third, there has been a dramatic increase in the number of cancer immunology clinical trials. Finally, the clinical success of immune modulators has increased the prestige of cancer immunology and subsequently the interest in it by the Yale immunology community. The CI Research Program is still invested in supporting the """"""""basic"""""""" research activities of the program, which is among the most productive in the field of immunology. In addition to its intrinsic value, this research creates a dynamic and fertile environment that adds to the cancer mission and which facilitates the recruitment of cancer immunologists. The central themes and scientific goals of the CI Program: 1. Identify cellular and molecular mechanisms that inhibit spontaneous immune responses against cancer cells in mouse models and in the clinic;2. Discover and test approaches for promoting anti-tumor immunity;3. Study the mechanistic links between inflammation, immune stimulation and cancer. Since the last CCSG submission, the Programs 34 members published 539 (2006-12) cancer related papers, of which 15% were intra-programmatic and 22% inter-programmatic. The total cancer research funding of the CI Program is $16M total costs, of which $13.2IVI is peer-reviewed and $3M is NCI-funded.

Public Health Relevance

The immune system, commonly. thought of as being dedicated to fighting infection, can be directed towards killing cancer cells. On the other hand, persistent poorly controlled immune responses can promote cancer. The goal of the Cancer Immunology program is to discover ways to promote immune eradication of cancer and to prevent immune-mediated induction of cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Yale University
New Haven
United States
Zip Code
Yanez, Diana A; Lacher, Richard K; Vidyarthi, Aurobind et al. (2017) The role of macrophages in skin homeostasis. Pflugers Arch 469:455-463
Langdon, Casey G; Platt, James T; Means, Robert E et al. (2017) Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor. Mol Cancer Ther 16:1041-1053
Kim, Bong-Sung; Ott, Veronica; Boecker, Arne Hendrick et al. (2017) The Effect of Antiseptics on Adipose-Derived Stem Cells. Plast Reconstr Surg 139:625-637
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2017) Spatially resolved and quantitative analysis of VISTA/PD-1H as a novel immunotherapy target in human non-small cell lung cancer. Clin Cancer Res :
Toki, Maria I; Cecchi, Fabiola; Hembrough, Todd et al. (2017) Proof of the quantitative potential of immunofluorescence by mass spectrometry. Lab Invest 97:329-334
Edelman, Martin J; Wang, Xiaofei; Hodgson, Lydia et al. (2017) Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). J Clin Oncol 35:2184-2192
Wang, Simeng; Yang, Xiaoyong (2017) Inter-organ regulation of adipose tissue browning. Cell Mol Life Sci 74:1765-1776
Acharya, Dhiraj; Wang, Penghua; Paul, Amber M et al. (2017) Interleukin-17A Promotes CD8+ T Cell Cytotoxicity To Facilitate West Nile Virus Clearance. J Virol 91:
Swartz, Kelsey L; Wood, Scott N; Murthy, Tushar et al. (2017) E2F-2 Promotes Nuclear Condensation and Enucleation of Terminally Differentiated Erythroblasts. Mol Cell Biol 37:
Menderes, Gulden; Bonazzoli, Elena; Bellone, Stefania et al. (2017) SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows promising antitumor activity in epithelial ovarian carcinoma with HER2/Neu expression. Gynecol Oncol 146:179-186

Showing the most recent 10 out of 631 publications